MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: Rhinitis, Allergic

Treatments: Drug: montelukast sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00771160

0476-397

2008_553

Details and patient eligibility

About

A clinical study evaluates the efficacy and safety of MK0476 in adult patients with Perennial Allergic rhinitis.

Enrollment: 120 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult Patients With Perennial Allergic Rhinitis

Exclusion criteria

• Patients Who Have Nasal Diseases (E.G., Nasal Polyp, Septonasal Arcuation, Hypertrophic Rhinitis), Upper Respiratory Infection, Sinusitis, Infectious Rhinitis And Those Disease Severe Enough To Interfere With Assessment Of Effectiveness
• Patients Who Have Rhinitis Medicamentosa, Or Nonallergic Rhinitis (E.G., Vasomotor Rhinitis, Eosinophilia Rhinitis)
• Patient Has A Disease Of The Cardiovascular, Hepatic, Renal, Hematologic Systems, Or Other Severe Disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

120 participants in 2 patient groups

1

Experimental group

Description:

MK0476 5mg

Treatment:

Drug: montelukast sodium

2

Experimental group

Description:

MK0476 10mg

Treatment:

Drug: montelukast sodium